Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Oral cavity

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    315 result(s) found for: Oral cavity. Displaying page 5 of 16.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2017-004248-39 Sponsor Protocol Number: PPI-microbiome Start Date*: 2018-01-04
    Sponsor Name:TARGID, KU Leuven
    Full Title: Effect of Proton Pump Inhibitors on the duodenal microbiome in healthy volunteers
    Medical condition: We will assess the effect of Proton Pump Inhibitors (PPI) on the duodenal, oral and fecal microbiota composition in healthy volunteers
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2010-022886-92 Sponsor Protocol Number: MWJ20100512V2 Start Date*: 2011-04-19
    Sponsor Name:Nottingham University Hospital NHS Trust
    Full Title: The effect of probiotics on the incidence of spontaneous bacterial peritonitis in patients with cirrhosis and ascites.
    Medical condition: cirrhosis and hepatic failure
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-005686-20 Sponsor Protocol Number: 004 Start Date*: 2012-08-20
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase II, Randomized, Active Comparator-Controlled Clinical Trial to Study the Safety, Tolerability, and Efficacy of MK-7655 + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone in Patients ...
    Medical condition: Patients with Complicated Intra-Abdominal Infection
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004862 10056570 Intra-abdominal infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Prematurely Ended) PT (Completed) GR (Completed) LT (Completed) LV (Completed) EE (Completed) BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2010-018399-25 Sponsor Protocol Number: MuSH_1.2 Start Date*: 2011-03-17
    Sponsor Name:Medizinische Universität Wien, Univ.Klinik für Zahn-,Mund-u.Kieferheilkunde,Klin.Abt.f.orale Chirurg
    Full Title: A randomized controlled trial: Photodynamic Treatment for the therapy of premalignant mucosal oral lesions.
    Medical condition: Leukoplakia and oral lichen ruber.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10062037 Leukoplakia LLT
    12.1 10062037 Leukoplakia PT
    12.1 10030983 Oral lichen planus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-003940-21 Sponsor Protocol Number: 46361 Start Date*: 2014-03-20
    Sponsor Name:University Medical Center Groningen
    Full Title: Systemic antibiotic therapy (amoxicillin plus metronidazole) as an adjunct to surgical treatment of peri-implantitis; a single blind randomized controlled study
    Medical condition: peri-implantitis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-001749-26 Sponsor Protocol Number: MK-3475-040 Start Date*: 2014-11-21
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase III Randomized Trial of MK-3475 (Pembrolizumab) versus Standard Treatment in Subjects with Recurrent or Metastatic Head and Neck Cancer
    Medical condition: Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067821 Head and neck cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) LT (Completed) DE (Completed) BE (Completed) PT (Completed) NL (Completed) HU (Completed) IT (Completed) ES (Completed) FR (Completed) PL (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2021-006031-25 Sponsor Protocol Number: UPALI Start Date*: 2022-08-10
    Sponsor Name:Charité - Universitätsmedizin Berlin
    Full Title: Treatment of patients with Lichen planus with the JAK-Inhibitor Upadacitinib (Rinvoq®) – a mono-centered double-blinded placebo controlled randomized pilot study (investigator-initiated trial)
    Medical condition: Patients with the chronic inflammatory skin disease Lichen planus will be treated with the JAK inhibitor upadacitinib.
    Disease: Version SOC Term Classification Code Term Level
    20.1 10017947 - Gastrointestinal disorders 10030983 Oral lichen planus PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-001913-34 Sponsor Protocol Number: TP-434-008 Start Date*: 2013-08-16
    Sponsor Name:Tetraphase Pharmaceuticals, Inc.
    Full Title: A Phase 3, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of Eravacycline Compared with Ertapenem in Complicated Intra-abdominal Infections
    Medical condition: Complicated Intra-abdominal Infections
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004862 10056570 Intra-abdominal infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) CZ (Completed) EE (Completed) LT (Completed) DE (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2016-002208-21 Sponsor Protocol Number: TP-434-025 Start Date*: 2016-09-27
    Sponsor Name:Tetraphase Pharmaceuticals, Inc.
    Full Title: A Phase 3, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of Eravacycline Compared with Meropenem in Complicated Intra-abdominal Infections
    Medical condition: Complicated Intra-abdominal Infections
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004862 10056570 Intra-abdominal infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) LV (Completed) EE (Completed) LT (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2019-003236-23 Sponsor Protocol Number: V503-049 Start Date*: 2020-03-11
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
    Full Title: A Phase 3, International, Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy, Immunogenicity, and Safety of the 9vHPV Vaccine, a Multivalent L1 Virus-li...
    Medical condition: Oral persistent infection caused by any of the human papillomavirus types 16, 18, 31, 33, 45, 52, and 58
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10006524 Buccal cavity papilloma LLT
    Population Age: Adults Gender: Male
    Trial protocol: FR (Trial now transitioned) ES (Ongoing) CZ (Trial now transitioned) DE (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-002308-24 Sponsor Protocol Number: NWHHT 08-01 Start Date*: 2008-10-23
    Sponsor Name:University Medical Centre Nijmegen St Radboud
    Full Title: A RANDOMISED STUDY OF DOCETAXEL/CISPLATIN/5-FLUOROURACIL (TPF) AS NEOADJUVANT CHEMOTHERAPY FOLLOWED BY CONCOMITANT CHEMORADIOTHERAPY (CRT) WITH CONVENTIONAL RADIOTHERAPY (RT) VERSUS CONCOMITANT CRT...
    Medical condition: locally advanced HNSCC
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-004398-22 Sponsor Protocol Number: 1 Start Date*: 2013-07-01
    Sponsor Name:Afd. A, OUH
    Full Title: intraperitoneal microdialysis after server peritonitis
    Medical condition: server peritonitis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2009-013317-10 Sponsor Protocol Number: GEN211 Start Date*: 2009-12-15
    Sponsor Name:Genmab A/S
    Full Title: An Open-label, Multi-Center, Phase I/II Trial Investigating the Pharmacokinetic profile of Zalutumumab, a Human Monoclonal Epidermal Growth Factor Receptor Antibody in non-curable patients with SCCHN
    Medical condition: Non-Curable Squamous cell carcinoma of the head and neck (SCCHN)
    Disease: Version SOC Term Classification Code Term Level
    12.0 10060121 Squamous cell carcinoma of head and neck LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) GB (Prematurely Ended) HU (Completed) SK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-002325-18 Sponsor Protocol Number: PemDoc Start Date*: 2016-01-29
    Sponsor Name:Med. Univ. Wien
    Full Title: Immunomodulation of pembrolizumab plus docetaxel for the treatment of r/m SCCHN after platinum failure
    Medical condition: head and neck cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2006-003381-33 Sponsor Protocol Number: EMR-62202-717 Start Date*: 2007-08-30
    Sponsor Name:Institute of Oncology Ljubljana
    Full Title: Induction chemotherapy followed by chemoradiation with cetuximab and cisplatin for inoperable squamous cell carcinoma of the head and neck.
    Medical condition: Inoperable squamous cell carcinoma of the head and neck.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-000689-13 Sponsor Protocol Number: HRT1vs2week.2018 Start Date*: 2018-07-11
    Sponsor Name:University hospital Brussel
    Full Title: Clinical pregnancy rate for frozen embryo transfer with HRT: a pilot study comparing 1 versus 2 weeks of treatment
    Medical condition: Subfertility in need of IVF and IVF-ICSI treatment
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004872 10042391 Subfertility LLT
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-000120-19 Sponsor Protocol Number: HN1901 Start Date*: 2020-05-05
    Sponsor Name:Cliniques universitaires Saint-Luc
    Full Title: Activity and safety of peptide-based immunotherapy in an umbrella window pre-operative opportunity phase II study in patients with squamous cell carcinoma of the head and neck.
    Medical condition: Head and neck cancer elective for surgery
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-006180-36 Sponsor Protocol Number: 22071-24071 Start Date*: 2011-01-18
    Sponsor Name:EORTC - European Organisation for Research and Treatment of Cancer
    Full Title: Randomized Phase III trial on postoperative chemoradiation in combination with anti EGFR-antibody versus postoperative chemoradiation in head and neck squamous cell carcinomas (HNSCC) with high ris...
    Medical condition: head and neck squamous cell carcinomas (HNSCC) with high risk of locoregional recurrence
    Disease: Version SOC Term Classification Code Term Level
    12.1 10067821 Head and neck cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) SI (Completed)
    Trial results: View results
    EudraCT Number: 2018-004078-89 Sponsor Protocol Number: 0001741 Start Date*: Information not available in EudraCT
    Sponsor Name:DIPARTIMENTO DI ONCOLOGIA-UNIVERSITA' DEGLI STUDI DI TORINO
    Full Title: RINSING WITH DESAMETASONE VERSUS RINSING WITH BENZIDAMINE IN THE PREVENTION OF MUCOSITES CORRELATED TO CHEMIORADIOTHERAPY IN PATIENTS WITH CANCERS OF THE CERVIC-FACIAL DISTRICT-Studio DEXWASH
    Medical condition: patients with cervico-facial neoplasms receiving concomitant chemoradiotherapy.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-005775-39 Sponsor Protocol Number: INCAGN2385-203 Start Date*: 2022-07-22
    Sponsor Name:Incyte Biosciences International Sarl
    Full Title: A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti–LAG-3) and INCAGN02390 (Anti–TIM-3) as First-Line Treatment in Participants With PD-L1–P...
    Medical condition: In participants with PD-L1–positive and systemic therapy–naive R/M SCCHN.
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071540 Head and neck cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) BE (Prematurely Ended) IT (Trial now transitioned) ES (Ongoing) GR (Trial now transitioned) PT (Trial now transitioned) NL (Ongoing) PL (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 31 17:36:18 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA